The PointMan cometh
Founded in Germany 25 years ago, EKF Diagnostics’ PLC HQ is currently in Cardiff, Wales, where the firm is pursuing the development of a molecular assay for specific cancer types.
Cancer
News • Oncology
One cancer – many tumors
In studies on prostate cancer, scientists from the German Cancer Research Center (DKFZ) simultaneously investigated the genetic and epigenetic development of the tumors.
Protein test instead of cystoscopy
A recent study from the Heidelberg-based company Sciomics, a spin-off from scientists from the German Cancer Research Center (DKFZ), has presented an advanced method to predict the recurrence of bladder cancer after surgery. The method, which can help avoid frequent cystoscopy examinations in a majority of patients, is based on an analysis of the protein composition of cancer tissue obtained…
Danes take pathology software worldwide
Having convinced medical labs across Denmark that its suite of image analysis software can provide a solution to the crushing burden of in vitro diagnostics (IVD), VisioPharm is offering it to pathologists worldwide
Bayer in cancer collaboration
Finnish pharma company Orion and German healthcare giant Bayer have entered into an agreement for the development and commercialisation of a novel drug targeting prostate cancer.
Final handover for the world’s most advanced proton therapy center
IBA (Ion Beam Applications S.A., EURONEXT), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed final contracts concluding the Essen project negotiation with the University Hospital of Essen (UK Essen).
Liver tumors: 3-D MRI scans better predict survival after chemo
In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized 3-D MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy – delivered directly through a tumor’s blood supply – is working.
A challenge for oncologists
‘The disease “cancer” is increasingly classified into sub-groups. Today, we are already dealing with a number of orphan diseases,’ says Professor Richard Greil MD, head of LIMCR at University Hospital Salzburg.
COCIR Raises Awareness of Industry Achievements On World Cancer Day 2014
Today is World Cancer Day 2014 and COCIR wants to take this opportunity to raise awareness of what our sector (medical imaging and health ICT) is contributing to the fight against cancer, by providing solutions for the prevention, early diagnosis and treatment of this devastating, ever-rising chronic disease.
Curie-Cancer and Servier continue joined cancer research
Curie-Cancer, the body which leads the Institut Curie's industry partner research activity, and Servier, today announce that they have renewed their partnership with the aim of identifying therapeutic targets for treating ‘triple negative’ breast cancers. The partnership will continue for a further three years.
Digital tomosynthesis for lung cancer screening
Screening for lung cancer saves lives. This fact has been documented by outcomes of the U.S. National Lung Screening Trial (NLST) which showed a 20% reduction in lung cancer-specific deaths in patients who had a chest CT screening. What is controversial is how to establish the radiology resources needed to perform exams for all the people who need it and then how to pay for the exams.
Breast cancer early detection – quo vadis?
Why is early detection of breast cancer so important? Professor Dr Walter Heindel, Director of the Institute of Clinical Radiology at University Hospital Münster, Germany, offers an unequivocal answer.
Hologic brings tomosynthesis to breast cancer screening
In May, 2013, the U.S. Food and Drug Administration (FDA) finally took the training wheels off tomosynthesis by approving the use of Hologic's new C-View 2D imaging in place of conventional 2D mammograms previously required as part of a breast tomosynthesis screening exam.
Article • MEDICA 2013
EndoMagnetics brings nanomedicine to breast cancer
It looks like a drug, it is injected in patients like a drug, but its acts like a medical device. Welcome to the new world of nanomedicine.
Article • MEDICA 2013
Genetically targeted medicine forges ahead
Healthcare is undergoing a major change set to offer a real prospect of far more genetically targeted treatments, according a leading human geneticist Sir John Burn, Professor of Clinical Genetics at Newcastle University, England.
Faster scanners, more parameters, better markers…
With MRI and CT scanners widely available in clinical routine, radiologists cull increasingly precise and relevant functional tumour information for diagnostics and monitoring purposes. Both modalities offer technological and methodological approaches, initiated by the discipline itself, that have become indispensable for certain frequent tumours.
European nanomedicine research
Cancer diagnostics - Nanotechnology is currently being used in oncology to improve early tumour detection, imaging procedures and targeting of cancer therapies. Cancer biomarkers, indicators that are being produced by the body in spreading tumour cells, play an important role in cancer detection, Dr. Jörg Raach reports
Despite population decrease, in 2020 cancer case will increase
In the country’s first scientific study to correlate the demographic changes and frequency of tumorous diseases, demographic changes have led scientists to forecast a significant increase in the number of cancerous diseases in coming years.
DIEP flap reconstruction
In France, every year 15,000 women undergo complete or partial mastectomy due to breast cancer. Only about a third of them, i.e. around 5,000 patients, use the possibilities reconstructive surgery offers and 70 percent of those women opt for an implant although it is associated with a risk of infection because the body might react negatively to the foreign object.
Mandatory tumour boards
The government of France takes cancer very seriously. With 150,000 deaths each year, this is the leading cause of mortality in the country. The national health system pays for 100% of the care.
Tumour boards cause staff problems
About 20 years ago the first tumour boards were set up in Germany. Initiated and led by surgeons, they not only invited oncologists, radiotherapists and radiologists to conferences but also, increasingly often, pathologists.
Article • Great Britain
£250 million for innovative cancer treatment
A major new cutting edge radiotherapy treatment will be available in the UK thanks to £250 million of government funding to build two new facilities in Manchester and London, Public Health Minister Anna Soubry confirmed on August, 1.
Re-evaluating the multidisciplinary approach to cancer care
A 2012 study analysing the care of cancer patients in the USA in 138 Veterans’ Administration hospitals (pub: Journal of the National Cancer Institute) questions the effectiveness of tumour board review. The study measured effectiveness by comparing the presence of tumour review boards with stage-specific quality of care and patient outcomes.
EuroMedLab 2013
Milan, Italy – The 20th European Congress of Clinical Chemistry and Laboratory Medicine certainly lived up to its claim as the EU’s largest event of its kind – 2,407 visitors and 4,786 delegates from 101 countries plus 82 exhibitors fanned out or arranged themselves over the event’s 3,500 square metres, Hanna Politis reports
Treating bladder cancer
Bladder cancer is highly challenging in terms of patient management and medical costs. As the fourth most frequent cancer in men and ninth in women in developed countries, although BC is a common disease it is still under-represented in public awareness and in cancer research .
